These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 19221369)
1. Evaluating off-label uses of anticancer drugs: time for a change. Sox HC Ann Intern Med; 2009 Mar; 150(5):353-4. PubMed ID: 19221369 [No Abstract] [Full Text] [Related]
3. Compendia and anticancer therapy under Medicare. Tillman K; Burton B; Jacques LB; Phurrough SE Ann Intern Med; 2009 Mar; 150(5):348-50. PubMed ID: 19221368 [TBL] [Abstract][Full Text] [Related]
4. Off-label cancer drug compendia found outdated and incomplete. Mitka M JAMA; 2009 Apr; 301(16):1645-6. PubMed ID: 19383947 [No Abstract] [Full Text] [Related]
5. Systematic review: reliability of compendia methods for off-label oncology indications. Abernethy AP; Raman G; Balk EM; Hammond JM; Orlando LA; Wheeler JL; Lau J; McCrory DC Ann Intern Med; 2009 Mar; 150(5):336-43. PubMed ID: 19221366 [TBL] [Abstract][Full Text] [Related]
6. Inadequacies of statutory drug compendia also affect the mental health field. Paczynski RP; Kruszewski SP Ann Intern Med; 2009 Sep; 151(5):364-5. PubMed ID: 19721028 [No Abstract] [Full Text] [Related]
7. Antineoplastic agents: comparing off-label uses among authoritative drug compendia. Thompson DF; Keefe CC Hosp Formul; 1993 Jul; 28(7):641-2, 647. PubMed ID: 10127046 [TBL] [Abstract][Full Text] [Related]
8. Quality of evidence in drug compendia supporting off-label use of typical and atypical antipsychotic medications. Paczynski RP; Alexander GC; Chinchilli VM; Kruszewski SP Int J Risk Saf Med; 2012 Jan; 24(3):137-46. PubMed ID: 22936056 [TBL] [Abstract][Full Text] [Related]
9. Rising Cost of Anticancer Medications in the United States. Jackson K; Nahata MC Ann Pharmacother; 2017 Aug; 51(8):706-710. PubMed ID: 28707550 [TBL] [Abstract][Full Text] [Related]
10. The diminishing value of the Physicians' Desk Reference and drug package inserts as a medical and legal standard of medical usage of pharmaceutical drugs. Burkhart CG J Drugs Dermatol; 2005; 4(4):414-5. PubMed ID: 16004013 [No Abstract] [Full Text] [Related]
11. Pharmacy team involvement in navigating the revenue cycle for high-cost medications in patients with cancer. Shank BR; Nguyen PAA; Pherson EC Am J Manag Care; 2017 Oct; 23(12 Spec No.):SP470-SP473. PubMed ID: 29087665 [No Abstract] [Full Text] [Related]
12. Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices. Mailankody S; Prasad V JAMA; 2016 Jul; 316(3):271-2. PubMed ID: 27149663 [No Abstract] [Full Text] [Related]
13. Specialty pharmacy management will become more intense. Collins S Manag Care; 2010 Oct; 19(10):20-3. PubMed ID: 21049783 [No Abstract] [Full Text] [Related]
14. Medicare is likely to pay for anticancer drugs. Charatan F BMJ; 2002 May; 324(7346):1118. PubMed ID: 12008721 [No Abstract] [Full Text] [Related]
15. Overspending driven by oversized single dose vials of cancer drugs. Bach PB; Conti RM; Muller RJ; Schnorr GC; Saltz LB BMJ; 2016 Feb; 352():i788. PubMed ID: 26932932 [No Abstract] [Full Text] [Related]
16. Coverage for hepatitis C drugs in Medicare Part D. Jung JK; Feldman R; Cheong C; Du P; Leslie D Am J Manag Care; 2016 May; 22(6 Spec No.):SP220-6. PubMed ID: 27266952 [TBL] [Abstract][Full Text] [Related]
18. Reimbursement for cancer treatment: coverage of off-label drug indications. American Society of Clinical Oncology J Clin Oncol; 2006 Jul; 24(19):3206-8. PubMed ID: 16717290 [TBL] [Abstract][Full Text] [Related]
19. Medicare finalizes ASP-plus-six reimbursement rate for outpatient drugs. Traynor K Am J Health Syst Pharm; 2013 Jan; 70(1):11-2. PubMed ID: 23261892 [No Abstract] [Full Text] [Related]